No Data
No Data
ClearPoint Neuro, Together With Its Partner Clinical Laserthermia Systems, Announces FDA Submission to Expand the Labeling of ClearPoint Prism(R) to Include 1.5 T MRI
The Five-year Returns Have Been Fantastic for ClearPoint Neuro (NASDAQ:CLPT) Shareholders Despite Underlying Losses Increasing
B. Riley Adjusts Price Target on ClearPoint Neuro to $28 From $20, Maintains Buy Rating
ClearPoint Neuro to Announce First Quarter 2025 Results May 13, 2025
ClearPoint Neuro Announces Full Market Release of ClearPoint Navigation Software Version 3.0 - Delivering the First End-to-End ClearPoint Navigation Solution to the Operating Room
Lake Street Maintains ClearPoint Neuro(CLPT.US) With Buy Rating